Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00330902 |
Recruitment Status :
Completed
First Posted : May 29, 2006
Last Update Posted : October 31, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Plasmodium Infections | Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) Drug: primaquine (PQ) plus SP+AS | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 104 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan |
Study Start Date : | January 2004 |
Actual Study Completion Date : | November 2004 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 1
Sulfadoxine pyrimethamine plus three daily doses of artesunate
|
Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS)
sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS) |
Experimental: 2
Sulfadoxine pyrimethamine plus artesunate plus primaquine
|
Drug: primaquine (PQ) plus SP+AS
single dose of primaquine on day 4 |
- P.falciparum parasitaemia detected by PCR on days 3,7 and 14. [ Time Frame: 14 days from start of treatment ]
- Presence of gametocytes detected by RT-PCR on days 3, 7 and 14. [ Time Frame: 14 days from start of treatment ]
- Packed Cell volume on days 7 and 14. [ Time Frame: Over 14 days from start of treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 3 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- infection with P.falciparum detected by PCR
Exclusion Criteria:
- pregnancy
- severe anaemia
- fever or other signs of illness
- history of allergy to sulfa drugs
- presence of other species of Plasmodium detected by microscopy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00330902
Sudan | |
Tropical Medicine Research Institute | |
Khartoum, Sudan |
Principal Investigator: | Badria B El Sayed, PhD | TMRI, Khartoum | |
Study Chair: | Omer Z Baraka, MD | Faculty of Medicine, University of Khartoum |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: | NCT00330902 History of Changes |
Other Study ID Numbers: |
SGS64 |
First Posted: | May 29, 2006 Key Record Dates |
Last Update Posted: | October 31, 2007 |
Last Verified: | October 2007 |
Keywords provided by London School of Hygiene and Tropical Medicine:
malaria subpatent parasitaemia dry season primaquine Plasmodium falciparum infection detected by PCR |
Additional relevant MeSH terms:
Infection Malaria Parasitemia Protozoan Infections Parasitic Diseases Sepsis Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes Artesunate Artemisinins Primaquine Pyrimethamine |
Sulfadoxine Fanasil, pyrimethamine drug combination Amebicides Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Antimalarials Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Renal Agents |